Kura Oncology Inc (KURA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kura Oncology Inc (KURA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8136
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer, including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigative drug candidate for mitogen-activated protein kinase pathway tumors; and KO-539, a small molecule inhibitor for the treatment of acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.

Kura Oncology Inc (KURA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Venture Financing 12
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Partnerships 13
Kura Oncology Enters into Research Agreement with University of Michigan 13
Merger 14
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 14
Licensing Agreements 15
Kura Oncology Amends Licensing Agreement with Janssen Pharma 15
Kura Oncology Amends its Licensing Agreement with University of Michigan 17
Equity Offering 18
Kura Oncology Raises USD77.1 Million in Public Offering of Shares 18
Kura Oncology Raises USD53.5 Million in Public Offering of Shares 19
Kura Oncology Raises USD50 Million in Public Offering of Shares 21
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 23
Kura Oncology Inc – Key Competitors 25
Kura Oncology Inc – Key Employees 26
Kura Oncology Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 06, 2018: Kura Oncology reports second quarter 2018 financial results and provides corporate update 28
May 08, 2018: Kura Oncology Announces First Quarter 2018 Financial Results 30
Mar 12, 2018: Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results 32
Aug 07, 2017: Kura Oncology Reports Second Quarter 2017 Financial Results 34
May 15, 2017: Kura Oncology Reports First Quarter 2017 Operational and Financial Results 35
Mar 14, 2017: Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results 37
Corporate Communications 38
Jul 31, 2018: Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer 38
Jan 03, 2017: Kura Oncology Appoints Steven Stein, M.D. to Board of Directors 39
Legal and Regulatory 40
Jun 26, 2017: Kura Oncology added to Russell 3000 index 40
Product News 41
10/28/2017: Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML 41
01/04/2017: Kura Oncology Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program 42
Clinical Trials 43
Oct 16, 2017: Kura Oncology Announces Late-Breaking Presentation on KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference 43
Apr 07, 2017: Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947 44
Apr 05, 2017: Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 45
Apr 05, 2017: Kura Oncology Presents Preclinical Data on KO-539 at the American Association for Cancer Research Annual Meeting 2017 46
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-539 at AACR Annual Meeting 2017 47
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-947 at AACR Annual Meeting 2017 48
Jan 04, 2017: Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Kura Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kura Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Kura Oncology Enters into Research Agreement with University of Michigan 13
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 14
Kura Oncology Amends Licensing Agreement with Janssen Pharma 15
Kura Oncology Amends its Licensing Agreement with University of Michigan 17
Kura Oncology Raises USD77.1 Million in Public Offering of Shares 18
Kura Oncology Raises USD53.5 Million in Public Offering of Shares 19
Kura Oncology Raises USD50 Million in Public Offering of Shares 21
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 23
Kura Oncology Inc, Key Competitors 25
Kura Oncology Inc, Key Employees 26
Kura Oncology Inc, Other Locations 27

List of Figures
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Kura Oncology Inc (KURA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Global Telecom Holding S.A.E. (GLTD):企業の財務・戦略的SWOT分析
    Global Telecom Holding S.A.E. (GLTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • TriLink BioTechnologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary TriLink BioTechnologies Inc (TriLink), a subsidiary of Maravai Life Sciences Inc, is a manufacturer of modified nucleic acid products. The company’s products include oligonucleotides, nucleotides, custom chemistry, DNA synthesis reagents, cleanamp PCR products, modified nucleoside triphospha …
  • Vita 34 AG (V3V):製薬・医療:M&Aディール及び事業提携情報
    Summary Vita 34 AG (Vita 34), formerly Vita 34 International AG, is an umbilical cord blood bank that collects, prepares, processes, deposits, and stores stem cells from umbilical cord blood. The company's products comprise vitaplus, vitaplus25, vitaplus50, vitapluscordtissue, vitapluscordtissue25, …
  • CK Infrastructure Holdings Ltd (1038):石油・ガス:M&Aディール及び事業提携情報
    Summary CK Infrastructure Holdings Limited (CKI), a subsidiary of CK Hutchison Holdings Limited, is an infrastructure investment company. It holds diversified investment interests across various sectors including energy, rail transportation, water, waste management, and other infrastructure related …
  • Mitochon Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Mitochon Pharmaceuticals Inc (Mitochon Pharma) is a biotech company that develops drugs for neurodegenerative and neuromuscular diseases. The company’s pipeline products comprise mitochondrial modulators such as MP-101, MP-201 and MP-301. It targets diseases such as batten disease, stroke, h …
  • Henry Schein Inc (HSIC):企業の財務・戦略的SWOT分析
    Henry Schein Inc (HSIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Helix Energy Solutions Group Inc (HLX):企業の財務・戦略的SWOT分析
    Summary Helix Energy Solutions Group Inc (Helix Energy) is an oil and gas company that provides offshore energy services. The company provides well intervention, subsea engineering and contracting services. Its well intervention services comprise riserless intervention and riser based operations, st …
  • MediWound Ltd (MDWD):医療機器:M&Aディール及び事業提携情報
    Summary MediWound Ltd (MediWound) is a biopharmaceutical company that on develops, manufactures and commercializes novel therapeutics based on its patented proteolytic enzyme technology. Its products address unmet needs in the areas of severe burns, chronic and other hard-to-heal wounds.The company’ …
  • Ascena Retail Group Inc:企業の戦略的SWOT分析
    Ascena Retail Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Adaptimmune Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Adaptimmune Ltd (Adaptimmune) a subsidiary of Adaptimmune Therapeutics plc operates as a clinical trials and pipeline company. The company engaged in developing T-cell receptors for T-cell therapy and SPEAR TCR therapies. Its clinical trials include synovial sarcoma trial, multiple myeloma t …
  • GrafTech International Ltd:企業の戦略・SWOT・財務分析
    GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report Summary GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • CGN Power Co Ltd (1816):電力:M&Aディール及び事業提携情報
    Summary CGN Power Co Ltd (CGN Power) a subsidiary of China General Nuclear Power Corp, is an electric utility. It generates and sells nuclear power and provides services. The company produces electricity using nuclear source. Under electricity sales contracts, CGN Power sells energy. It also has int …
  • Tubacero S. de RL de CV:企業の戦略・SWOT・財務分析
    Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report Summary Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Brady Corporation (BRC):企業の財務・戦略的SWOT分析
    Brady Corporation (BRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Bespak Europe Ltd:企業の製品パイプライン分析2018
    Summary Bespak Europe Ltd (Bespak), a subsidiary of Consort Medical plc is a medical device company that provides inhalation systems. The company provides products such as inhalation devices, injectables, medical check valves and nasal products. Its inhalation devices comprise dose counting actuator …
  • Lixil Group Corporation (5938):企業の財務・戦略的SWOT分析
    Lixil Group Corporation (5938) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Oil & Gas Development Co Ltd (OGDC):企業の財務・戦略的SWOT分析
    Oil & Gas Development Co Ltd (OGDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • YTL Power International Berhad (YTLPOWR):企業の財務・戦略的SWOT分析
    YTL Power International Berhad (YTLPOWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • TissueGen Inc:企業の製品パイプライン分析2018
    Summary TissueGen Inc (TissueGen) is a medical device company that develops fiber for advance drug delivery, nerve regeneration and tissue engineering. The company’s products comprise pharmaceutical fibers, growth factor fibers and stent. It offers pharmaceutical fibers and growth factor fibers. Tis …
  • First Bank of Nigeria Ltd:企業の戦略・SWOT・財務情報
    First Bank of Nigeria Ltd - Strategy, SWOT and Corporate Finance Report Summary First Bank of Nigeria Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆